ABSTRACT. Silver nanopaticles (AgNPs) and gold nanoparticles (AuNPs) have various applications in medical healthcare and various biological properties such as anti-inflammation, anti-cancer, and antiangiogenesis. In this study, we investigated the effect of AgNPs and AuNPs on cytokine production via the mitogen-activated protein kinase pathway in leukemic cell lines (T-lymphocytic Jurkat and monocytic U937 cells). We found that both AgNPs and AuNPs inhibited cell proliferation of leukemic cell lines. AgNPs inhibited TNF-α, while AuNPs inhibited interleukin-2 production in Jurkat cells, in which inhibition of cytokines is involved in the extracellular-signal regulated protein kinase but not the c-Jun N-terminal kinase pathway. In U937 cells, AuNPs inhibited interleukin-6 but stimulated TNF-α production in
INTRODUCTION
Leukemia is a form of malignancy that occurs in the blood, and thus is known as blood cancer. In this disease, abnormal hematopoietic stem cells are present in the bone marrow, which causes abnormal proliferation and differentiation as well as an increased number of immature white blood cells (Piller, 2003; Brown et al., 2012) . Patients suffering from leukemia are treated with chemotherapy; however, chemotherapy causes a number of side effects. Thus, other options have been developed to treat leukemia and reduce these side effects.
Nanoparticles have many applications and are studied an important area of research known as nanotechnology. In this study, we chose silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) as an alternative treatment method that may reduce side effects. AgNPs and AuNPs are the most commonly used nanotechnology and have numerous applications in medical healthcare. They have various biological properties, including anti-microbial (Panácek et al., 2009; Alarcon et al., 2012) , anti-inflammatory (Wong et al., 2009) , and antiangiogenesis properties (Arvizo et al., 2011) . AgNPs and AuNPs upregulate the expression of the proinflammatory genes interlukin-1 (IL-1), interlukin-6 (IL-6), and tumor necrosis factor (TNF-α) in macrophage cells (Yen et al., 2009) . Furthermore, AuNPs have been shown to significantly increase the expression of IL-6 and TNF-α in the kidneys of rats (Khan et al., 2013) . Cytokines are signaling molecules that mediate and regulate cellular activities. Proinflammatory cytokines such as IL-2, IL-6, and TNF-α regulate immunity, inflammation, and hematopoiesis (O'Shea et al., 2008) . Cytokines are important for the mitogen-activated protein kinase (MAPK) pathway, which is one of many pathways that require cytokines for proper functioning (Kyriakis and Avruch, 2001) .
MAPK pathway proteins contain conserved activation sites and structures that link extracellular signals to the machinery that controls fundamental cellular processes, such as growth, proliferation, differentiation, migration, and apoptosis (Chang and Karin, 2001; Platanias, 2003) . Groups of MAPKs have been characterized in mammals, including extracellular signal regulated protein (ERK), c-Jun N-terminal kinase (JNK), and the p38 MAPK (Dhillon et al., 2007) . In previous studies, AgNPs exposure activated p38 MAPK through the nuclear factor-E2-related factor-2 and nuclear factor-kappaB (NF-kB) signaling pathways, subsequently inducing DNA damage, cell cycle arrest, and apoptosis in Jurkat cells (Eom and Choi, 2010) . Furthermore, apoptosis has been associated with the generation of reactive oxygen species and JNK activation was induced in NIH3T3 cells (Hsin et al., 2008) . AuNPs activates p38 MAPK by regulating the expression of genes to induce osteogenic differentiation in mesenchymal stem cells (Yi et al., 2010) .
In the present study, we investigated the effects of AgNPs and AuNPs on IL-2, IL-6, and TNF-α production via MAPK pathways in human leukemic cell lines (Jurkat and U937). We hypothesized that changes in MAPKs activity and expression, induced by nanoparticles, would influence cytokine production in leukemic cells. Our results may be applied for AgNPs and AuNPs in the treatment of leukemia.
MATERIAL AND METHODS

Nanoparticles preparation
In this study, gold and silver nanoparticles were synthesized using the chemical reduction method, also known as the Turkevich method, using trisodium citrate (Fluka, Buchs, Switzerland). Nanoparticles were synthesized as stock solution at a maximum concentration of 500 ppm. The nanoparticles were estimated to range from 10-50 nm in diameter (Turkevich et al., 1951; Eustis, 2006) .
AgNPs
AgNPs were prepared from an aqueous 50 mL solution of 0.001 M AgNO 3 (Sigma Aldrich, St. Louis, MO, USA), which was heated to boiling point and stirred using a magnetic stirrer. Next, 5 mL 1% trisodium citrate was added dropwise. The AgNP solution color changed from clear to yellow. Stirring was continued until the solution had cooled to room temperature. Finally, a drop of 0.3% polyvinyl pyrrolidone (PVP) (Sigma Aldrich) was added to prevent aggregation (Wang et al., 2005; Solomon et al., 2007) .
AuNPs
AuNPs were prepared from 20 mL 0.001 M HAuCl 4 (Sigma Aldrich). This solution was heated to boiling on a magnetic stirrer. To the rapidly stirred boiling solution, 2 mL 1% trisodium citrate was added. The AuNP solution color changed from the original yellow to a deep red color. It was then stirred until cooled to room temperature. Finally, a drop of 0.3% PVP was added to prevent aggregation.
Cell culture
The human leukemic T cell line Jurkat (ATCC, Manassas, VA, USA) was cultured in RPMI-1640 (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum, plated in 12-well plates, and incubated overnight at 37°C with 5% CO 2 .
The human monocytic cell line U937 (ATCC) was cultured in RPMI 1640 (Hyclone) supplemented with 10% fetal bovine serum. U937 cells were activated with 10 nM phorbol 12-myristate 13-acetate (PMA) (Sigma Aldrich), seeded on 12-well plates, and incubated overnight at 37°C with 5% CO 2 .
Cell viability assay
Cell viability was evaluated using a modified XTT assay kit (Sigma Aldrich). Jurkat and U937 cells were seeded at a density of 1 x 10 6 cells/mL in complete RPMI medium on 96-well plates and treated with AgNPs (2.5-15 ppm), AuNPs (5-50 ppm), and vehicle control (sodium citrate and PVP) incubated at 37°C in a humidified atmosphere with 5% CO 2 for 24 h. Untreated cells were used as a negative control and dimethyl sulfoxide was used as a positive control. After 24 h, 20 µL XTT working solution was added to each well and the plates were incubated for 4 h. Absorbance was measured using a microtiter plate reader (BioTek, Winsooki, VT, USA) at a wavelength of 450 nm and a reference 690 nm. The relative cell viability (%) related to control wells containing cells without nanoparticles was calculated using the following equation
Enzyme-linked immunosorbent assay (ELISA) of IL-2, IL-6, and TNF-α Jurkat cells (1 x 10 6 /mL) were treated with AgNPs, with concentrations ranging from 0-7.5 ppm and various concentrations of AuNPs from 0-30 ppm. As a positive control, 12.5 ng/ mL PMA plus 0.25 µg/mL lectin from Phaseolus vulgaris/Leucoagglutinin (PHA-L) (Sigma Aldrich) were used to stimulate control cells. The cells were incubated at 37°C with 5% CO 2 for 12 h before the addition of PMA/PHA and were then incubated for additional 12 h. Cells were incubated for a total of 24 h with various concentrations of AgNPs, AuNPs, or PMA/PHA. After the incubation, culture media was collected for detection of IL-2 and TNF-α levels.
U937 cells (1 x 10 6 /mL) were treated with AgNP concentrations ranging from 0-7.5 ppm and various concentrations of AuNPs from 0-30 ppm. As a positive control, 1 µg/mL lipopolysaccharide (LPS) (Sigma-Aldrich) was used to activate control cells. The cells were incubated at 37°C with 5% CO 2 for 12 h before stimulation with LPS and then incubated for additional 12 h. Cells were incubated for a total of 24 h with various concentrations of AgNPs, AuNPs, or LPS. Following incubation, culture media was collected for detection of IL-6 and TNF-α levels. In addition to the experimental wells, 1% sodium citrate and 0.3% PVP was used as a vehicle control.
Cytokines release (IL-2, IL-6, and TNF-α) of AgNP-and AuNP-treated cells were quantified using an ELISA kit (R&D Systems, Minneapolis, MN, USA) and absorbance measured using a microtiter plate reader (Perkin Elmer, Waltham, MA, USA) at a wavelength of 450 nm with a reference 540 nm. The cytokine level was normalized to the total protein concentration of cell pellets using the Bradford method with the Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA).
Western blot analysis
Jurkat cells and U937 cells (1 x 10 6 /mL) were treated with 7.5 ppm AgNPs, 25 ppm AuNPs, and vehicle control (sodium citrate and PVP) for different time periods ranging from 0-24 h in triplicate. Both cell lines were collected and washed with phosphate-buffered saline, pH 7.4, 3 times. Cellular lysate was prepared using lysis buffer containing 25 mM Tris-phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane-N,N,Nꞌ,Nꞌ-tetraacetic acid, 10% glycerol, 1% Triton ® X-100, and added protease inhibitor cocktail (Sigma-Aldrich). An equivalent amount of sample was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The membrane was blocked for 1 h at room temperature with Tris-buffered saline containing 5% non-fat milk. Next, the membranes were incubated overnight at 4°C with the primary antibody diluted 1:1000-4000 against p-ERK1/2, ERK1/2, p-SAPK/JNK, SAPK/ JNK, and β-actin (Cell Signaling, Danvers, MA, USA) and then incubated with horseradish peroxidase-conjugated secondary antibody 1:2000-4000 (Cell Signaling) for 45 min. After application of the secondary antibody, triplicate washes with Tris-buffered saline containing Tween 20 were conducted. Finally, visualization of protein expression was achieved using enhanced chemiluminescence western blotting substrate (Pierce, Rockford, IL, USA) before exposure to Hyperfilm-enhanced chemiluminescence (GE Healthcare, UK). Densitometry analysis was carried out using the NIH ImageJ software (Bethesda, MD, USA).
Statistical analysis
Statistical analyses were assessed by one-way analysis of variance. The Graph Pad Prism software version 4.00 (Graph Pad Software Inc., San Diego, CA, USA) was used. A P value < 0.05 was considered to be significant.
RESULTS
Inhibition of leukemic cell lines proliferation by AgNPs and AuNPs
In this study, we examined whether AgNPs and AuNPs inhibited the proliferation of leukemic cells (Jurkat and U937) in a concentration-dependent manner. Cells were treated with AgNPs (2.5-15 ppm) and AuNPs (5-50 ppm) for 24 h and cell viability was analyzed using the XTT assay. The results are reported as means ± standard error from 3 independent experiments. The results showed that proliferation inhibition of leukemic cells was dose-dependent with a median inhibition concentration (IC 50 value) of AgNPs of 9.8 and 12. In this experiment, we determined whether sodium citrate and PVP (vehicle control) inhibited the proliferation of leukemic cells (Jurkat and U937). The results showed that sodium citrate and PVP did not inhibit proliferation of leukemic cells (data not shown).
Effect of AgNPs and AuNPs on IL-2, TNF-α, and IL-6 production
In this study, we analyzed the expression of cytokine production in leukemic cell lines (Jurkat and U937). Both leukemic cell lines were treated with different concentrations of AgNPs, AuNPs, and vehicle control for 24 h.
Effect of AgNPs and AuNPs on inhibition of PMA/PHA-induced IL-2 and TNF-α production in Jurkat cells
Jurkat cells were pretreated with different concentrations of AgNPs, below the IC 50 (9.8 ppm) for 12 h. Next, PMA/PHA was added and then incubated for additional 12 h. Using an ELISA, we found no significant effect on IL-2 production (data not shown). However, AgNps significantly decreased TNF-α production compared to PMA/PHA alone (Figure 3) . We found that AgNPs inhibited PMA/PHA-stimulated TNF-α production in a dose-dependent manner. Next, we investigated whether different concentrations of AuNPs below the IC 50 (43.3 ppm) caused significant decrease in the release of IL-2 from Jurkat cells (Figure 4) . However, AuNPs caused no significant decrease in TNF-α production (data not shown).
Effect of AgNPs and AuNPs on inhibition of LPS-induced IL-6 and TNF-α production in U937 cells
U937 cells were pretreated with different concentrations of AgNPs, below the IC 50 (12.6 ppm) for 12 h. Next, LPS was added and incubated for additional 12 h. Using ELISA, we found no significant effect on IL-6 and TNF-α production (data not shown). Next, we investigated dif- ferent concentrations of AuNPs below the IC 50 (45.6 ppm). We found that AuNPs significantly decreased the release of IL-6 ( Figure 5 ) and increased TNF-α production ( Figure 6 ) in U937 cells. Figure 3 . Effect of AgNPs on inhibition of PMA/PHA-induced IL-2 and TNF-α production. Jurkat cells were treated with with 0 to 7.5 ppm of AgNPs, sodium citrate and polyvinyl pyrrolidone (PVP) (vehicle control) for 12 h and then activated with PMA/PHA for further 12 h. TNF-α production was analyzed by ELISA. Data are reported as means ± SE from three independent experiments. Statistical analysis was carried out with one-way ANOVA followed by the Tukey multiple comparison test compared with positive controls (PMA/PHA) (*P < 0.05, **P < 0.01). Effect of AuNPs on inhibition of PMA/PHA-induced IL-2 and TNF-α production. Jurkat cells were treated with 0 to 30 ppm of AuNPs, sodium citrate and polyvinyl pyrrolidone (PVP) (vehicle control) for 12 h and then activated with PMA/PHA for further 12 h. IL-2 production was analyzed by ELISA. Data are reported as means ± SE from three independent experiments. Statistical analysis was carried out with one-way ANOVA followed by the Tukey multiple comparison test compared with positive controls (PMA/PHA) (**P < 0.01, ***P < 0.001). Figure 6 . Effect of AuNPs on inhibition of LPS-induced IL-6 and TNF-α production. U937 cells were treated with 0 to 30 ppm of AuNPs, sodium citrate and polyvinyl pyrrolidone (PVP) (vehicle control) for 12 h and then activated with LPS for further 12 h. TNF-α production was analyzed by ELISA. Data are reported as means ± SE from three independent experiments. Statistical analysis was carried out with one-way ANOVA followed by the Tukey multiple comparison test compared with positive controls (LPS) (*P < 0.05, **P < 0.01).
Figure 5. Effect of AuNPs on inhibition of LPS-induced IL-6
and TNF-α production. U937 cells were treated with 0 to 30 ppm of AuNPs, sodium citrate and polyvinyl pyrrolidone (PVP) (vehicle control) for 12 h and then activated with LPS for further 12 h. IL-6 production was analyzed by ELISA. Data are reported as means ± SE from three independent experiments. Statistical analysis was carried out with one-way ANOVA followed by the Tukey multiple comparison test compared with positive controls (LPS) (*P < 0.05).
Effect of AgNPs and AuNPs on MAPK activation and expression in leukemic cells
In our previous results, we showed that AgNPs and AuNPs induced cytokine release from the leukemic cells. As the MAPK pathway is involved in cytokine production, we further investigated the effects of AgNPs and AuNPs on ERK and JNK proteins in leukemic cells. Concentrations of 7.5 ppm AgNPs and 25 ppm AuNPs were used to treat cells to investigate ERK and JNK protein expression at different time points using western blot analysis. Protein expression level was analyzed based on the intensity of the protein bands from 3 independent experiments.
Effect of AgNPs and AuNPs on ERK pathway in Jurkat cells
From our previous results, we showed that AgNPs inhibited TNF-α production and AuNPs inhibited IL-2 production. We suspected that inhibition of IL-2 and TNF-α release involved the MAPK pathway. Jurkat cells were treated with AgNPs 7.5 ppm or control (sodium citrate and PVP) for 5 min to 24 h and the expression of p-ERK1/2, ERK, and β-actin was analyzed using western blot analysis ( Figure 7A and B) . The data showed that the relative level of ERK in the cells treated with AgNPs 7.5 ppm was suppressed at all time points compared to those of control ( Figure 7C ). Although p-ERK expression was reduced, likely because of the lack of ERK protein at most time points (Figure 7D ), the relative ratio of p-ERK1/2/ERK protein level was significantly decreased from 5 to 30 min, suggesting that non-phosphorylated ERK was observed at these time points ( Figure 7E ).
Next, we studied the effects of AuNPs on p-ERK1/2 and ERK expression in Jurkat cells. Cells were treated with 25 ppm AuNPs or control for 5 min to 24 h. Western blot analysis revealed expression of p-ERK1/2, ERK, and β-actin ( Figure 8A and B) . The results showed that 25 ppm AuNPs increased ERK expression compared to the control at all time points (Figure 8C) . Despite the increase in ERK protein, the relative ratio of the p-ERK1/2/ERK protein level was significantly reduced at 5 min to 1 h, suggesting that phosphorylated ERK1/2 is suppressed at these time points ( Figure 8D and E).
Effect of AuNPs on JNK pathway in U937 cells
We showed in our previous results that AuNPs inhibited IL-6 production and activated TNF-α production release, which may be involved in the MAPK pathway. U937 cells were treated with 25 ppm AuNPs or control (sodium citrate and PVP) for 5 min to 24 h. Western blot analysis showed expression of p-JNK (46 and 54 kDa), JNK (46 and 54 kDa), and β-actin (45 kDa) ( Figure 9A, B) . The data showed that JNK expression level did not changed with AuNPs treatment at any time points ( Figure 9C ), whereas AuNPs inhibited p-JNK expression at 5 to 30 min compared with to the control ( Figure 9D and E).
DISCUSSION
The anti-proliferation activities of AgNPs and AuNPs on many cancerous cells have been studied in vitro, including human hepatoma HepG2 cells, human lung cancer cells, and Figure 7 . Western blot analysis of the effect of AgNPs on the activity and expression of ERK pathway proteins in Jurkat cells. Cells were treated with AgNPs 7.5 ppm or vehicle control (sodium citrate or PVP) for 5 min to 24 h. Lane C = negative control (untreated cells) at 24 h. A. Expression of p-ERK1/2 (42, 44 kDa), ERK1/2 (42, 44 kDa), and actin (45 kDa) after treatment with sodium citrate and PVP 7.5 ppm. B. Expression of p-ERK1/2 (42, 44 kDa), ERK1/2 (42, 44 kDa) and actin (45 kDa) after treatment with AgNPs 7.5 ppm. C. D. E. Data represent the relative p-ERK1/2, ERK and p-ERK1/2/ERK protein levels, and are reported as means ± SE from three independent experiments. Statistical analyses were carried out with one-way ANOVA followed by the Tukey multiple comparison test compared with vehicle control (sodium citrate and PVP) (*P < 0.05, **P < 0.01, ***P < 0.001).
Continued on next page Relative p-ERK, ERK and p-ERK/ERK protein levels. Data are reported as means ± SE from three independent experiments. Statistical analysis was carried out with one-way ANOVA followed by the Tukey multiple comparison test compared with sodium citrate and PVP (vehicle control) (*P < 0.05, **P < 0.01, ***P < 0.001).
Continued on next page protein levels and are reported as means ± SE from three independent experiments. Statistical analysis was carried out with one-way ANOVA followed by the Tukey multiple comparison test compared with sodium citrate and PVP (vehicle control) (*P < 0.05, **P < 0.01, ***P < 0.001).
Continued on next page 6 acute myeloid leukemia cell lines, showing IC 50 values ranging from 0.5-20 ppm of AgNps (Kim et al., 2009; Zhou and Wang, 2012; Guo et al., 2013) . AuNPs inhibited the proliferation of multiple myeloma cell lines and human lung adenocarcinoma cells with IC 50 values ranging from 5-60 ppm (Bhattacharya et al., 2007; Choi et al., 2012) . The amount of inhibition depends on the cell type, dose, and length of treatment.
Our study showed that AgNPs inhibited the proliferation of Jurkat cells and U937 cells with IC 50 values of 9.8 and 12.6 ppm, respectively. At higher concentrations, AuNPs inhibited proliferation of Jurkat (IC 50 of 43.3 ppm) and U937 cells (IC 50 of 45.6 ppm).
AgNPs showed more significant inhibitory efficacy compared to AuNPs because AgNPs are more easily oxidized than AuNPs, leading to oxidative stress in the cell membrane (Bogumiła et al., 2013) . We also demonstrated that AgNPs and AuNPs affect PMA/PHAinduced cytokine production in Jurkat cells and LPS-induced cytokine production in U937 cells. Cytokines are signaling molecules that mediate and regulate cellular activities. IL-2 and IL-6 regulate cell proliferation and cytokine secretion, whereas TNF-α regulates immunity, inflammation, and apoptosis (Bradley, 2008; O'Shea et al., 2008) . Other studies have found that AgNPs and AuNPs upregulated cytokine expression in other cell types (Yen et al., 2009; Khan et al., 2013) . However, we found that AgNPs inhibit TNF-α in Jurkat cells and AuNPs inhibit IL-2 and IL-6 in Jurkat and U937 cells in a concentration-dependent manner. Suppression of IL-2 and IL-6, which are important for regulating cell proliferation in Jurkat and U937 cells, is a potential mechanism that inhibits cell proliferation. However, AgNPs did not inhibit IL-2 and IL-6 and have higher toxicity than AuNPs based on the IC 50 values, suggesting that mechanisms other than antiproliferation reduce cell survival. Interestingly, TNF-α was reported to have the opposite effect in different cell types, in which TNF-α was inhibited by AgNPs in Jurkat cells but stimulated by AuNPs in U937 cells. Inhibition of TNF-α may lead to reduced cellular responses and activities, whereas induction may lead to cell apoptosis. Whether through inhibition or induction of TNF-α in different cell types, cell survival is reduced.
Previous studies reported the effects of nanoparticles on the MAPK signaling pathway in many cell types. AgNPs induced apoptosis through reactive oxygen species and JNK-MAPK via the mitochondria pathway in NIH3T3 fibroblast cells (Hsin et al., 2008) . AgNPs can increase the expression of p38 in Caenorhabditis elegans (Lim et al., 2012) , AgNPs decreased ERK signaling, and AuNPs significantly reduced p-ERK levels in epithelial cells (Comfort et al., 2011) . In this study, we investigated the effects of AgNPs and AuNPs on MAPK signaling pathway activities and expression, focusing on ERK and JNK, in leukemic cells. Our results showed that AgNPs suppressed ERK, whereas AuNPs increased ERK expression. However, based on the ratio of p-ERK/ERK, both AgNPs and AuNPs attenuated levels of ERK phosphorylation for the first 30 min after treatment in Jurkat cells. ERK signaling is known to induce cell proliferation and cell survival. The association between cytokine production and the MAPK signaling pathway has been described previously; IL-2 acts through ERK signaling in proliferation and cell survival (Gaffen, 2001 ). AuNPs inhibit IL-2 and reduce ERK phosphorylation, indicating that anti-proliferation of Jurkat cells is caused by suppression of IL-2 production via the ERK pathway. Reduction of TNF-α by AgNPs likely also involves the ERK pathway. In previous studies, TNF-α activated NF-kB to regulate FLICE-like inhibitory protein long form as a mediator of ERK1/2 phosphorylation, leading to the promotion of cell survival (Marques-Fernandez et al., 2013) . Other pathway proteins may also be involved in nanoparticle inhibition of IL-2 and TNF-α production such as NF-kB or p38, for which further studies should be conducted. Furthermore, AgNPs and AuNPs did not change the activity or expression of JNK protein (data not shown), suggesting that JNK is not involved in nanoparticle inhibition of cytokine production in Jurkat cells.
JNK signaling suppresses tumor cells possibly by inducing apoptosis (Kennedy et al., 2003) . In contrast, JNK signaling may activate NF-kB, leading to the suppression of apoptosis (Bubici et al., 2004) . In addition, TNF-α can promote cell survival, previous studies have shown that IL-6 expression, regulated by JNK, mediates NF-kB-mediated cell survival in renal epithelial cells (de Haij et al., 2005) . Our results showed AuNPs inhibited IL-6, stimulated TNF-α, and reduced JNK phosphorylation in U937 cells, while AuNPs did not affect ERK protein (data not shown). This suggests that the JNK pathway, but not ERK, is involved in cytokine production, particularly IL-6, resulting in anti-proliferation of U937 cells. TNF-α and JNK are known to modulate apoptosis, but the roles of JNK signaling in relation to TNF-α production to promote cell death and survival is not clearly understood. Stimulation of TNF-α by AuNPs may involve other signal pathway proteins such as NF-kB, activator protein 1, and Bid.
In this report, we investigated whether AgNPs and AuNPs had anti-leukemia effects against human leukemic cell lines. Both AgNPs and AuNPs showed effects on cytokine production via either the ERK or JNK pathway, depending on the cell type and nanoparticle type, resulting in reduction of cell growth. For leukemic T-cells, Jurkat cells responded to both AgNPs and AuNPs via ERK, whereas monocytic U937 cells responded to only AuNPs via the JNK pathway. This inhibition of cytokines and reduction of phosphorylated ERK and JNK is unlikely to have resulted from nanoparticle-induced toxicity of the cells because the concentrations of AgNPs and AuNPs used were well below the IC 50 . Other signaling pathway proteins cannot be ruled out as having roles in anti-proliferation. Our data provides useful information regarding possible treatments since partial mechanisms of anti-proliferation in each leukemic cell type are known. In addition to anti-proliferation properties, nanoparticles may process other properties, which could damage cell functions or even induce cell death or apoptosis, and further studies should be carried out to examine this. Moreover, the effects of nanoparticles on normal blood cells should be also investigated to evaluate cell toxicity in normal cells. Our findings suggest that nanoparticles can be applied for alternative co-treatment, combined with conventional treatments for leukemia.
